Literature DB >> 30688930

The relationship between joint hypermobility and subacromial impingement syndrome and adhesive capsulitis of the shoulder.

Arzu Atici1, Ilknur Aktas1, Pinar Akpinar1, Feyza Unlu Ozkan1.   

Abstract

OBJECTIVE: Joint hypermobility (JH) is a clinical condition in which the joints move beyond the expected physiological range of motion. JH can be accompanied by many musculoskeletal complaints. One of the common causes of musculoskeletal pain is shoulder pain. The aim of this study was to investigate the relationship between subacromial impingement syndrome (SAIS), shoulder adhesive capsulitis (AC), and JH in patients with shoulder pain.
METHODS: Patients aged between 18 and 70 years who presented at the physical medicine and rehabilitation outpatient clinic and who were diagnosed with SAIS or AC in a clinical and physical examination were included in the study. Patients in the same age group without musculoskeletal system pain were included in a control group. All of the cases were assessed for hypermobility using the Beighton score for generalized joint hypermobility (GJH), and the revised 1998 Brighton criteria for benign joint hypermobility syndrome (BJHS).
RESULTS: Of the 124 cases included in the study, 71 (57.3%) were female and 53 (42.7%) were male. There was no case of GJH in the AC group. There were 2 (4.50%) cases in the SAIS group and 3 (7.5%) in the control group. BJHS was found in 4 (10%) cases in the AC group, 6 (13.63%) in the SAIS group, and 2 (5%) cases in the control group. There was no statistically significant difference between groups in terms of JH (p>0.05). The Beighton scores of the AC group were statistically lower those of the control group (p<0.05).
CONCLUSION: The results of this study indicated no significant difference between the SAIS group, the AC group, and the control group in terms of GJH and BJHS. The fact that Beighton scores were lower in the AC group than in the control group suggests that the probability of developing AC in those with JH may be lower.

Entities:  

Keywords:  Adhesive capsulitis of the shoulder; joint hypermobility; subacromial impingement syndrome

Year:  2018        PMID: 30688930      PMCID: PMC6323568          DOI: 10.14744/nci.2017.35119

Source DB:  PubMed          Journal:  North Clin Istanb        ISSN: 2536-4553


Joint hypermobility (JH) is a clinical condition characterized an excess range of motion in a joint beyond the physiological range of motion [1]. When the condition is asymptomatic, it is termed generalized joint hypermobility (GJH); however, when it is associated with symptoms such as arthralgia, soft tissue damage, and joint instability, it is referred to as benign joint hypermobility syndrome (BJHS) [2]. JH is more common in young people; the incidence decreases with age. The incidence in the general population has been reported to range between 10% and 20% [3]. An increase in the proportion of collagen or collagen subtypes, such as type III/type I has been detected in JH [4, 5]. This abnormal collagen structure causes joint laxity, and fragility of the connective tissue increases. This condition predisposes the individual to musculoskeletal pathologies. Shoulder pain is one of the widely seen causes of musculoskeletal system pain, and affects some 7% to 34% of the population [6]. Subacromial impingement syndrome (SAIS) and adhesive capsulitis (AC) of the shoulder are the most common causes of shoulder pain. SAIS occurs as a result of impingement of soft tissues, especially the supraspinatus muscle, the subacromial bursa, and the biceps tendon between the humerus and the coracoacromial arch [7]. SAIS may develop secondary to structural or functional etiologies [8]. In the literature, it has been suggested that JH may contribute to clinical manifestations of SAIS [9]. AC is a disease characterized by shoulder pain and a restricted range of joint motion which affects a reported 2% to 5% of the population [10]. AC may manifest without any etiology, or it may develop secondary to a local problem (shoulder rotator cuff rupture, calcific tendonitis, trauma) or systemic disease (diabetes mellitus, hypo- or hyperthyroidism) [11, 12]. The basic event in its pathogenesis is the development of fibrosis in the joint capsule as a result of an accumulation of fibroblasts and myofibroblasts in type I and type III collagen tissue [13, 14]. As a result, the range of motion of the joint is both actively and passively restricted. Both SAIS and AC cause pain and disability. In this study, the aim was to investigate the association of SAIS and AC, which are etiological agents of joint pain with different pathophysiological mechanisms, with JH.

MATERIALS AND METHODS

A total of 124 patients aged between 18 and 70 years who presented at the outpatient clinic of physical medicine and rehabilitation with complaints of shoulder pain and who were diagnosed with SAIS or AC based on their medical history and a clinical examination, and age-matched healthy control subjects without any musculoskeletal complaints were enrolled in the study. Before the research was initiated, the participants were informed about the study design, and written informed consent was obtained. The subacromial injection test (SET) was administered to cases with positive Hawkins-Kennedy test, Neer test, and painful arc test results. SET-positive patients were included in the SAIS group. SET was performed using an anterior approach after injecting 5 cc 1% lidocaine solution with a 21-G needle tip inserted just below the acromion and advanced into the subacromial space. The SET test was considered positive if the patient’s pain was relieved and active and/or passive range of motion of the affected shoulder improved 80% [15, 16]. For the diagnosis of AC, the diagnostic criteria defined by Bulgen et al. [17] were used: shoulder pain persisting for at least 1 month, nighttime pain or the inability to lie on the affected side, restriction of active and passive range of motion of the shoulder joint in all directions, and at least 50% restriction of external rotation in the affected shoulder compared with the normal contralateral shoulder [17, 18]. Patients with a history of inflammatory disease, malignancy, shoulder trauma within the previous 6 months, shoulder surgery, or a plain radiogram that revealed the presence of osteoarthritis or calcification of the shoulder joint were not included in the study. Demographic data of all of the study participants were recorded. The duration of the shoulder pain and characteristics of the shoulder pain (activity pain, nighttime pain) of the cases diagnosed as AC and SAIS were noted. The Beighton hypermobility scoring system was used to evaluate GJH, and a score of ≥4 points was accepted as indicative of GJH (Table 1). BJHS was evaluated based on the revised 1998 Brighton criteria (Table 2) [19, 20].
TABLE 1

Beighton hypermobility score

RightLeft
Dorsiflexion of the fifth metocarpal joint (>90°)11
Passive apposition of the thumb to the flexor11
aspect of the forearm
Passive hyperextension of the elbow (>10°)11
Passive hyperextension of the knee(>10°)11
Palms of the hands resting flat on the floor with the patient standing erect with fully extended knees1
Total9
TABLE 2

Revised 1998 Brighton criteria

Major criteria:

Beighton score of 4/9 or greater (either currently or historically)Arthralgia for longer than 3 months in 4 or more joints
Minor criteria:

Beighton score of 1,2, or 3/9 (0,1,2, or 3/9 if aged >50 years)Arthralgia in one to three joints or back pain for more than 3 months, spondylolysis, spondylolysis/spondylolisthesisDislocation/subluxation in more than one joint or in one joint on more than one occasionSoft tissue rheumatism with >3 lesions (e.g., bursitis, tenosynovitis, epicondylitis)Marfanoid habitus (tall, slim, span/height ratio >1.03, upper/lower segment ratio <0.89, arachnodactyly (positive Steinberg/wrist signs)Cutaneous lesions: striae, hyperextensibility, thin skinEye signs: Drooping eyelids, myopia, or antimongoloid slantVaricose veins or hernia or uterine/rectal prolapse
Required diagnostic criteria:

2 major criteria1 major and 2 minor criteria4 minor criteriaPresence of BJHS in first degree relatives and 2 minor criteria*diagnosis of joint hypermobility syndrome is ruled out in the presence of collagen tissue diseases, such as Marfan syndrome and Ehler-Danlos syndrome.*Criteria Major 1 and Minor 1 are mutually exclusive, as are Major 2 and Minor 2.
Beighton hypermobility score The ethics committee of Istanbul Fatih Sultan Mehmet Training and Research Hospital approved of this study.

Statistical analyses

IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp., Armonk, NY, USA) was used for the statistical analysis of the study data. Normal distribution was evaluated using the Shapiro-Wilk test. Descriptive statistics of mean, SD, and frequencies were calculated. A one-way analysis of variance was used for intergroup comparisons of quantitative data with a normal distribution pattern. For intergroup comparisons of parameters with non-normal distribution, the Kruskal-Wallis and Mann-Whitney U tests were used. A chi-square test and the Fisher-Freeman-Halton exact test were applied to compare qualitative data. Statistical significance was evaluated at p<0.05.

RESULTS

A total of 124 (female: n=71, 57.3%; male: n=53, 42.7%) participants were included in the study. The mean age was 54.69±9.07 years (range: 29–70 years). The cases were divided into AC (n=40), SAIS (n=44), and healthy control (n=40) groups. No statistically significant intergroup difference was found with regard to mean age, gender, or hand dominance (p>0.05). (Table 3) In addition, no statistically significant intergroup difference was detected between the AC and SAIS groups with respect to duration of the shoulder pain, or the occurrence of nighttime and activity pain (p>0.05) (Table 4).
TABLE 4

Characteristics of pain encountered in the AC and SAIS groups

AC groupSAIS groupp
Region, n (%)
 Right shoulder20 (50%)22 (50%)
 Left shoulder19 (47.50%)19 (43.18%)0.635
 Both shoulders1 (2.50%)3 (6.81%)
Duration of pain (months; mean±SD)7.58±8.5 (5.5)14.73±27.03(4)0.715
Shoulder pain, n (%)
 Nighttime pain5 (12.50%)9 (20.45%)0.620
 Activity pain3 (7.50%)3 (6.81%)
 Both nighttime and activity pain32 (80%)32 (72.72%)

AC: Adhesive capsulitis; SAIS: Subacromial impingement syndrome

Revised 1998 Brighton criteria Demographic and clinical characteristics of the groups AC: Adhesive capsulitis; SAIS: Subacromial impingement syndrome Characteristics of pain encountered in the AC and SAIS groups AC: Adhesive capsulitis; SAIS: Subacromial impingement syndrome In the entire study group, 5 (4.03%) cases of GJH were observed and 12 (9.68%) cases of BJHS. GJH was seen in 2 (4.50%) SAIS patients and in 3 (7.5%) controls; no cases of GJH were detected in the AC group. BHJS was present in 4 (10%) patients in the AC group, 6 (13.63%) of the SAIS group, and 2 (5%) of the controls. No statistically significant intergroup difference was found between the GJH and BJHS groups (p>0.05). However, the Beighton hypermobility scores of the AC patients were statistically significantly lower than those of the control group (p<0.05) (Table 5).
TABLE 5

Comparison of Beighton score, GJH, and BJHS between groups

AC groupSAIS groupControl groupp
Beighton score (mean±SD)0.28±0.640.68±1.180.93±1.27 (0)0.045*
GJH n (%)
 Present0 (0%)2 (4.5%)3 (7.5%)0.279
 Absent40 (100%)42 (95.5%)37 (92.5%)
BJHS n (%)
 Present4 (10%)6 (13.6%)2 (5%)0.482
 Absent36 (90%)38 (86.4%)38 (95%)

p<0.05

AC: Adhesive capsulitis; BJHS: Benign joint hypermobility syndrome; GJH: Generalized joint hypermobility; SAIS: Subacromial impingement syndrome

Comparison of Beighton score, GJH, and BJHS between groups p<0.05 AC: Adhesive capsulitis; BJHS: Benign joint hypermobility syndrome; GJH: Generalized joint hypermobility; SAIS: Subacromial impingement syndrome

DISCUSSION

We investigated the association between SAIS and AC, the most frequently encountered shoulder diseases in our clinical practice, and JH. No relationship with JH was observed in the 2 patient groups or the control group; however, the Beighton hypermobility score was significantly lower in the AC group compared with the control group. As an asymptomatic condition, GJH may confer advantages in activities as dance and gymnastics [21]. When it becomes symptomatic, it is called BJHS and may include musculoskeletal problems. Aktas et al. [22] detected a positive correlation between carpal tunnel syndrome and BJHS. In another study, BJHS was described as a potential risk factor for lumbar disc herniation [23]. Higher rates of JH have been reported in fibromyalgia patients relative to a control group [24, 25]. Gürer et al. [26] asserted that GJH may increase the risk of knee osteoarthritis. Joint injuries related to hypermobility are often seen. In a study performed with professional football players, the incidence of injuries to the lower extremities, and particularly femur and ankle traumas, was greater in individuals with GJH [27]. GJH increases the risk of musculoskeletal system injuries and adversely affects the recovery period and the quality of healing due to the impaired collagen structure [20]. The shoulder is one of the joints most often affected by hypermobility. In a study conducted by Tobias et al. [28], the authors reported that in cases of GJH in adolescents, it was most frequently accompanied by shoulder, knee, or ankle pain. In another study, it was reported that the incidence of generalized body pain was higher in a group of patients diagnosed with BJHS and Hypermobile Type Ehler-Danlos Syndrome when compared with a healthy control group. The patients also frequently experienced neck pain, followed by shoulder pain. The Western Ontario Instability Index (WOSI) scores used to evaluate shoulder function in these patients were lower than those recorded in the control group [29]. The risk of joint instability increases in cases with JH. Although subluxations are not a specific characteristic of BJHS, recurrent subluxations indicate the severity of laxity and local muscular weakness [21]. Cameron et al. [30] detected a correlation between GJH and glenohumeral joint instability independent of gender or race and suggested the use of GJH scoring as a risk factor for joint instability. Similarly to our study, Terzi et al. [31] investigated the impact of GJH on the etiopathogenesis of AC, and compared cases with AC and SAIS with respect to JH. They detected lower rates of GJH and BJHS in the AC group, and suggested that GJH might be a protective factor against the development of AC in cases with joint pain. In our study we did not find any statistically significant difference between cases with SAIS and AC in terms of GJH. The Beighton hypermobility scores in the SAIS group were not significantly different from those of the control group, but were lower in the AC group. This finding suggests a potentially lower risk of developing AC in cases with JH. However, this subject requires additional studies performed with a larger number of cases. The incidence of JH decreases with age. Since the median age of our study population was 54 years, we might have observed a smaller percentage of GJH in our study participants. Monitoring young individuals with JH may enable a healthier solution for shoulder complaints in later years. In conclusion, we did not detect any difference in GJH and BJHS between the SAIS and AC groups. The lower Beighton hypermobility scores in the AC group relative to the control group suggest that there may be a lower risk of AC in cases with JH.
TABLE 3

Demographic and clinical characteristics of the groups

AC groupSAIS groupControl groupp
Age (years; mean±SD)57.55±7.6553.57±10.5453.08±8.140.051
Gender
 Female18 (45%)27 (61.36%)26 (65%)0.154
 Male22 (55%)17 (38.63%)14 (35%)
Dominant hand
 Right38 (95%)43 (97.72%)37 (92.5%)0.519
 Left2 (5%)1 (2.27%)3 (7.5%)

AC: Adhesive capsulitis; SAIS: Subacromial impingement syndrome

  29 in total

1.  The revised (Brighton 1998) criteria for the diagnosis of benign joint hypermobility syndrome (BJHS).

Authors:  R Grahame; H A Bird; A Child
Journal:  J Rheumatol       Date:  2000-07       Impact factor: 4.666

2.  Expression of growth factors, cytokines and matrix metalloproteinases in frozen shoulder.

Authors:  T D Bunker; J Reilly; K S Baird; D L Hamblen
Journal:  J Bone Joint Surg Br       Date:  2000-07

3.  The frequency of hypermobility and its relationship with clinical findings of fibromyalgia patients.

Authors:  O Faruk Sendur; Gulcan Gurer; Gulnur Tasci Bozbas
Journal:  Clin Rheumatol       Date:  2006-04-25       Impact factor: 2.980

Review 4.  Joint hypermobility.

Authors:  Alan Hakim; Rodney Grahame
Journal:  Best Pract Res Clin Rheumatol       Date:  2003-12       Impact factor: 4.098

5.  Is local subacromial corticosteroid injection beneficial in subacromial impingement syndrome?

Authors:  Kenan Akgün; Murat Birtane; Ulkü Akarirmak
Journal:  Clin Rheumatol       Date:  2004-12       Impact factor: 2.980

Review 6.  Hypermobility and the hypermobility syndrome.

Authors:  Jane V Simmonds; Rosemary J Keer
Journal:  Man Ther       Date:  2007-07-20

7.  Diagnostic values of clinical diagnostic tests in subacromial impingement syndrome.

Authors:  M Caliş; K Akgün; M Birtane; I Karacan; H Caliş; F Tüzün
Journal:  Ann Rheum Dis       Date:  2000-01       Impact factor: 19.103

8.  Hypermobility in women with fibromyalgia syndrome.

Authors:  Demet Ofluoglu; Osman Hakan Gunduz; Evren Kul-Panza; Zeynep Guven
Journal:  Clin Rheumatol       Date:  2005-10-16       Impact factor: 2.980

Review 9.  Benign joint hypermobility syndrome: evaluation, diagnosis, and management.

Authors:  Michael R Simpson
Journal:  J Am Osteopath Assoc       Date:  2006-09

10.  Course and prognosis of shoulder symptoms in general practice.

Authors:  M L Reilingh; T Kuijpers; A M Tanja-Harfterkamp; D A van der Windt
Journal:  Rheumatology (Oxford)       Date:  2008-04-14       Impact factor: 7.580

View more
  1 in total

1.  Impingement on the internet: evaluating the quality and readability of online subacromial impingement information.

Authors:  Christopher Erian; Michael Erian; Sumit Raniga
Journal:  BMJ Open Sport Exerc Med       Date:  2021-11-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.